XML 19 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Notes to the income statement
6 Months Ended
Jun. 30, 2023
Notes to the income statement  
Notes to the income statement

Note 5.    Notes to the income statement

​

5.1Revenues and other income

​

​

​

​

​

​

​

    

​

​

​

First-half

​

First-half

In thousands of euros

    

2023

    

2022

Revenue

 

1,901

​

67

Total revenue

 

1,901

​

67

Tax credits

 

3,631

​

3,210

Subsidies

 

3

​

6

Other

 

1,087

​

109

Other operating income

 

4,721

​

3,325

Total revenue and other income

 

6,622

​

3,392

​

Revenues

​

The Company invoiced CTTQ for $2.1 million on May 22, 2023 (the total invoice corresponds to the milestone payment of $2 million following the IND approval from the NMPA, and an additional billing of $0.1 million). On July 19, 2023, the Company received $1.9 million after deducting the withholding tax of $0.2 million3.

3The Company invoiced €1.9 million on May 22, 2023 (corresponds to the milestone payment of €1.8 million euros, and an additional invoicing of €0.1 million) and received on July 19, 2023, €1.7 million after deduction of withholding tax for €0.2 million. The exchange rate on the invoice date was 1.082 dollar for one euros.

Other operating income

Tax credits are the 2023 CIR as of June 30, 2023, in the amount of €3.6 million, including €1.0 million for the R&D Tax Research Credit of Inventiva Inc.

The other income is mainly composed by:

●the reinvoicing to CTTQ of a share of costs incurred as of June 30, 2023 in the Phase I clinical pharmacology study for the ongoing NATiV3 Phase III trial in the amount of €0.3 million;
●the specific costs to be reinvoiced to CTTQ relating to CRO accrued liabilities, for an amount of €0.7 million.

5.2Operating expenses

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Marketing – 

​

​

​

​

​

​

Research and

​

Business

​

General and

​

​

First-half 2023

​

development

​

development

​

administrative

​

​

In thousands of euros

    

costs

    

expenses

    

expenses

    

Total

Disposables

 

(943)

 

—

 

—

 

(943)

Energy and liquids

 

(479)

 

—

 

—

 

(479)

Patents

 

(257)

 

—

 

—

 

(257)

Studies

 

(42,847)

 

—

 

—

 

(42,847)

Maintenance

 

(459)

 

—

 

—

 

(459)

Fees

 

(61)

 

—

 

(1,884)

 

(1,945)

IT systems

 

(440)

 

(9)

 

(50)

 

(498)

Support costs (including taxes)

 

—

 

—

 

(343)

 

(343)

Personnel costs

 

(7,065)

 

(126)

 

(2,347)

 

(9,538)

Depreciation, amortization and provisions

 

(1,061)

 

—

 

(104)

 

(1,166)

Other operating expenses

 

(450)

 

(570)

 

(2,084)

 

(3,105)

Total operating expenses

 

(54,062)

 

(705)

 

(6,812)

 

(61,580)

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Marketing – 

​

​

​

​

​

​

Research and

​

Business

​

General and

​

​

First-half 2022

​

development

​

development

​

administrative

​

​

In thousands of euros

    

costs

    

expenses

    

expenses

    

Total

Disposables

 

(920)

 

—

 

—

 

(920)

Energy and liquids

 

(368)

 

—

 

(92)

 

(460)

Patents

 

(227)

 

—

 

—

 

(227)

Studies

 

(20,530)

 

—

 

—

 

(20,530)

Maintenance

 

(466)

 

—

 

(55)

 

(521)

Fees

 

(103)

 

(1)

 

(2,026)

 

(2,129)

IT systems

 

(428)

 

(7)

 

(42)

 

(477)

Support costs (including taxes)

 

—

 

—

 

(355)

 

(355)

Personnel costs

 

(5,891)

 

(111)

 

(2,198)

 

(8,201)

Depreciation, amortization and provisions

 

(594)

 

—

 

(105)

 

(699)

Other operating expenses

 

(340)

 

(159)

 

(1,973)

 

(2,471)

Total operating expenses

 

(29,866)

 

(278)

 

(6,847)

 

(36,991)

​

​

Personnel costs and headcount

​

​

​

​

​

​

​

​

​

​

​

    

​

    

Marketing —

    

​

    

​

​

​

Research and

​

Business

​

General and

​

​

First-half 2023

​

development

​

development

​

administrative

​

​

In thousands of euros

​

costs

​

expenses

​

expenses

​

Total

Wages, salaries and similar costs

 

(4,399)

 

(104)

 

(1,191)

 

(5,694)

Payroll taxes

 

(1,222)

 

(10)

 

(476)

 

(1,708)

Provisions for retirement benefit obligations

 

(61)

 

—

 

(29)

 

(90)

Share-based payments

 

(1,383)

 

(13)

 

(650)

 

(2,046)

Total personnel costs

 

(7,065)

 

(126)

 

(2,347)

 

(9,538)

​

The Company has 117 employees at June 30, 2023, of which 105 are employed by Inventiva S.A. and 12 are employed by Inventiva Inc.

​

​

​

​

​

​

​

​

​

​

​

    

​

    

Marketing —

    

​

    

​

​

​

Research and

​

Business

​

General and

​

​

First-half 2022

​

development

​

development

​

administrative

​

​

In thousands of euros

    

costs

    

expenses

    

expenses

    

Total

Wages, salaries and similar costs

 

(3,671)

 

(94)

 

(1,147)

 

(4,913)

Payroll taxes

 

(1,107)

 

(8)

 

(412)

 

(1,527)

Provisions for retirement benefit obligations

 

(78)

 

—

 

(40)

 

(118)

Share-based payments

 

(1,034)

 

(9)

 

(600)

 

(1,643)

Total personnel costs

 

(5,891)

 

(111)

 

(2,198)

 

(8,201)

​

The Company has 109 employees at June 30, 2022, of which 102 are employed by Inventiva S.A. and 7 are employed by Inventiva Inc.

​

5.3Other operating income and expenses

Other operating income and expenses break down as follows:

​

​

​

​

​

​

​

    

First-half

​

First-half

In thousands of euros

    

2023

    

2022

Reversal of provision – Tax disputes

​

—

​

180

Reversal of provision – AMR penalties

​

—

​

114

Total other operating income

​

—

​

294

Disposals of assets

 

—

​

(9)

Late payment interest on CIR 2013-2015

​

—

​

(121)

Transaction costs

​

(44)

​

(32)

Total other operating expenses

 

(44)

​

(163)

Other operating income (expenses)

 

(44)

​

131

​

5.4Financial income and expenses

​

For the first six months ended June 30, 2023 and June 30, 2022

​

​

​

​

​

​

​

    

First-half

​

First-half

In thousands of euros

    

2023

    

2022

Income from cash equivalents

 

564

​

140

Foreign exchange gains

 

187

​

4,019

Fair value variation gains / losses

​

1,623

​

—

Total financial income

 

2,373

​

4,159

Interest cost

 

(1,941)

​

(120)

Foreign exchange losses

​

(683)

​

(49)

Losses on fair value variation

​

—

​

—

Other financial expenses

 

(23)

​

(7)

Total financial expenses

 

(2,646)

​

(177)

Net financial income

 

(273)

​

3,983

​

In the first half of 2023, financial income is mainly related to change in fair value of the warrants issued to the EIB.

Financial expenses mainly include interest related to the PGE loans, the PPR loans and the EIB loan, financial interest on lease liabilities, and foreign exchange losses.

​

5.5Income tax

The income tax calculation for interim periods is set out in note 3.3 “Specific disclosure requirements for unaudited interim financial statements.”

As the imputation of tax benefits on tax losses of Inventiva S.A., at short or mid-term, were considered unlikely due to the growth phase of the company and regarding the nil projected tax rate as of December 31, 2023, no current taxes were recorded as of June 30, 2023, for Inventiva S.A.

5.6Basic and diluted loss per share

​

Basic earnings (loss) per share are calculated by dividing net income (loss) attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the period.

​

​

​

​

​

​

​

    

First-half

​

First-half

In euros

    

2023

    

2022

Net loss for the period

 

(55,269)

​

(29,466)

Weighted average number of shares outstanding used to calculate basic/diluted loss per share(1)

 

42,044,796

​

40,864,457

Basic/diluted loss per share

 

(1.31)

​

(0.72)

(1)

In accordance with IAS 33.19, basic/diluted earnings per share exclude treasury shares held by the Group as of June 30, 2023.

​

As a loss was recorded in the first half of 2023 and 2022, diluted earnings (loss) per share are the same as basic earnings (loss) per share. Share-based payment plans (BSAs, BSPCEs, AGAs and PAGUP) are not included as their effects would be anti-dilutive.